导航高风险和超高风险多发性骨髓瘤:挑战和新兴战略
Matthew J Rees1, Mattia D'Agostino2, Lisa B Leypoldt3,4
1Division of Hematology, Mayo Clinic, Rochester, MN.
概括
高危多发性骨髓瘤患者需要更好的治疗方法. 实现可测量的残留疾病负面性是改善结果的关键,无论治疗方法如何,特别是使用新型免疫疗法.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 新型疗法已经改善了多发性骨髓瘤的结果,但高危人群 (HR) 仍然面临早期进展和死亡.
- 超高风险 (uHR) MM被定义为24-36个月内死亡,HRMM是36-60个月内死亡.
研究的目的:
- 审查当前的治疗策略,并确定改善高风险新诊断多发性骨髓瘤 (NDMM) 结果的关键因素.
- 突出可测量的残留疾病负面影响在减轻不良预后因素的重要性.
主要方法:
- 审查现有的临床试验数据和文献,重点关注HR和uHR多发性骨髓瘤.
- 对预后标记物的分析,包括细胞遗传学,外骨髓性疾病和基因表达造型.
主要成果:
- 可测量的残留疾病负面性是缓解不良预后的主要因素,无论基线特征或治疗如何.
- 适合HR移植的NDMM的推治疗包括四倍诱导/巩固,自身干细胞移植和双倍维护.
- 对于不适合移植的NDMM,也建议进行四倍疗法.
结论:
- 实现和保持可测量的残留疾病负面性对于改善HR多发性骨髓瘤的生存率至关重要.
- 目前的治疗策略包括针对移植资格量身定制的密集诱导/巩固和维持疗法.
- 结合BCMA导向免疫疗法的未来研究为推进HR NDMM治疗提供了重大潜力.
更多相关视频
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.7K
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.4K
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
